It can be a miserable time of month – especially for those who suffer extreme pain….but cannabis can help.
It is a fact of life and comes almost like clockwork. Some 60% of woman have mild cramps during their period and about 5% to 15% report period pain that’s so severe that it affects their daily activities. Experts aren’t quite sure why some have more pain others. Since this is a little research area, some scientist rely on everyone’s body is different. Symptoms include aching, throbbing pain or a feeling of pressure in the abdomen, pain in the hips, lower back and inner thighs along with nausea, dizziness and headaches. The good news is cannabis can help painful menstrual cramps.
Some simple ways to help reduce the pain is to ensure you have enough rest and avoid caffeine, alcohol and cigarettes. Cannabis is proven to have medical benefits, especially with inflammation and pain relief. Marijuana expands blood vessels which helps reduce cramps, and relieve headaches and other minor pain. It is also fast acting, often quicker than natural or other medicines.
Photo by IRA_EVVA/Getty Images
While edibles and smoking may help, many women are turning to topicals and cannabis suppositories for pain relief. With 50% of the country having access to legal weed, it can be considered a viable option. While more research needs to be done, anecdotal data indicts it can help and quickly.
Suppositories or cannabis tampons can provide quick pain relief. They take around 15 minutes to work, and directly affect the pelvis muscles and uterus, relaxing the insides and reducing tension. Best to use them right before bed or when you’re going to be laying down for a while. Relax, and be sure to wear something for the sake of your underwear.
Another way is cannabis bath salts. An effective way to combat pain and period cramps is relaxation, which can be facilitated with a nice long bath and some fancy bath salts. They can provide relief for up to 5 hours but might leave you a little loopy afterwards.
A cannabis balm can be used anywhere on the body, including the the site of the cramps. It is an analgesic, so if the cramps are particularly powerful, add a spoonful of the balm to the insides of your vagina and let it melt. Do this when you have time to let the balm do it’s work.
Studies have shown can also lift moods, and more than just temporarily. Marijuana can also help minimize mood swings and bring overall mood stability. Cannabis can aid in the regulation of our brain’s neurotransmitters which can help us get better control of our emotions.
Tariffs are the word of the day – but marijuana consumers need to be ready to see a change also.
From apples to automobiles, hundreds of industries are trying to figure out the new tariffs. What is clear is prices are going up on a random amount of things. But, why is a surprise, is cannabis consumers are being hit by the tariffs also. Although cannabis itself cannot be imported or exported due to federal restrictions, the industry heavily relies on international suppliers for key components like vaporizer hardware, packaging, and cultivation equipment.
For instance, products sourced from China now face cumulative tariffs as high as 45%, including a 10% increase imposed in February 2025. Similarly, imports from Canada and Mexico face 25% tariffs. These measures have particularly affected items like vape cartridges, batteries, and specialized packaging materials, which are difficult to source domestically at competitive prices. As a result, many cannabis companies are passing these increased costs down the supply chain to consumer
The financial burden of these tariffs is substantial. Analysts estimate that most cannabis businesses lack the margin flexibility to absorb a 10%-15% cost increase. This has led to higher retail prices for products like pre-rolls and vaporizers, potentially pushing consumers toward cheaper, unregulated black-market alternatives. Such a shift raises concerns about product safety and could undermine the legal market’s growth.
Additionally, the tariffs have caused stock prices of major cannabis companies like Tilray Brands and Canopy Growth to decline by 5%-10%, reflecting investor concerns over profitability.Smaller businesses, already constrained by high taxes and limited banking access, are particularly vulnerable to these economic pressures.
Efforts to mitigate tariff-related expenses include exploring alternative manufacturing locations in countries like Malaysia or India. However, transitioning production is complex and time-consuming due to logistical hurdles and regulatory compliance requirements. Domestic production is another option but often comes with higher costs and limited capacity.
Packaging regulations in many states exacerbate the situation by requiring child-resistant designs, further limiting affordable domestic alternatives. Some companies are exploring sustainable packaging solutions as a long-term strategy to reduce dependence on volatile international markets.
The ongoing trade tensions show no signs of easing under Trump’s administration, leaving cannabis businesses with little choice but to adapt quickly. Strategies such as diversifying suppliers, investing in automation, and innovating with local materials may help companies weather the storm. However, without significant policy shifts or financial support mechanisms, the industry faces a challenging road ahead.
There is a buzz about sore throats today. While they are most common in colder months, spring allergies bring the pain also. This is often due to postnasal drip, which is when mucus from the nose and sinuses drains down the back of the throat, causing irritation and a scratchy feeling. Overuse of the voice, like talking loudly or singing for long periods, can tire out and strain the muscles in your throat, causing them to feel sore. The good news is cannabis can help a sore throat.
For those seeking natural alternatives to manage cold symptoms, cannabis is emerging as a promising option for throat irritation. Increasing research at medical center specifically targeting sore throats shows early insights. The data suggests cannabinoids and terpenes could offer symptom relief through their unique properties.
Photo by Esther Kelleter / EyeEm/Getty Images
Cannabis contains compounds like THC and CBD, which studies indicate possess anti-inflammatory properties that may reduce throat swelling and irritation. Terpenes such as eucalyptol—found in some strains—are traditionally associated with decongestant effects, potentially easing respiratory discomfort. These components work synergistically to calm inflamed tissues, though their direct impact on sore throats requires further clinical validation.
Smoking cannabis while ill remains controversial due to potential throat irritation from heat and smoke. Instead, experts recommend gentler options:
Edibles/lozenges: THC or CBD-infused products bypass inhalation, delivering localized relief without aggravating the throat.
Cannabis tea: Warm beverages with cannabis extracts may soothe scratchy throats while providing hydration.
Beyond direct throat relief, cannabis may improve overall wellness during illness. THC’s appetite-stimulating properties can combat reduced hunger, while its relaxing effects might promote restorative sleep. CBD’s muscle-relaxing qualities could help alleviate the body aches often accompanying colds.
While preliminary findings are encouraging, users should consult healthcare providers before combining cannabis with conventional cold medications due to potential interactions. Starting with low-dose CBD products may offer benefits without psychoactive effects. As legalization expands, more targeted research is expected to clarify cannabis’s role in respiratory health.
Innovative cannabis formulations—from throat-calming lozenges to anti-inflammatory teas—are redefining how we approach minor ailments. For those navigating cold season, these plant-based solutions present a compelling fusion of traditional herbal wisdom and modern cannabinoid science
Part of the cannabis industry supported the new president, betting he was going to move and move quickly on cannabis – the White House finally commented.
The cannabis industry has been a boon for consumers, medical patients, veterans and legal states, but for the thousands of mom and pop businesses is has been a roller coaster. With a huge demand, it would seem to be easy money, but the federal, tax, and banking restrictions have made it difficult to grow and expand. Part of the industry were all for the new administration assuming they would support positive change, but many in the new cabinet and the House Speaker Mike Johnson are foes. Now the White House finally comments on marijuana industry…and it doesn’t show a clear path.
The administration’s current stance on marijuana reform is marked by inaction, despite campaign promises and earlier signals of support for cannabis-related reforms. A White House official recently confirmed that “no action is being considered at this time” regarding marijuana policy, leaving advocates and industry stakeholders uncertain about the administration’s priorities.
During his campaign, the resident expressed support for rescheduling marijuana under the Controlled Substances Act (CSA), which would move it from Schedule I to Schedule III, easing restrictions on medical use and enabling cannabis businesses to access banking and tax benefits. However, since taking office, no concrete steps have been taken to advance this initiative. A DEA hearing on rescheduling, initially planned for January 2025, was postponed due to procedural appeals and remains unscheduled.
The president has also voiced support for state autonomy in cannabis policy and endorsed state-level legalization initiatives, such as Florida’s failed 2024 ballot measure for recreational marijuana. While this reflects a more favorable stance compared to his first term, his administration has yet to prioritize federal reforms like the SAFE Banking Act, which would facilitate banking services for cannabis businesses. Efforts to include such measures in a government funding bill late last year were unsuccessful.
The delay in federal action has significant implications for the cannabis industry. Rescheduling marijuana could alleviate financial burdens by eliminating restrictions under IRS Code Section 280E and promoting medical research. However, the stalled process leaves businesses navigating regulatory uncertainties and limited financial access.
While stakeholders continue lobbying for reform, the administration appears focused on other priorities such as immigration and foreign policy. Advocates hope the President will leverage his influence to advance cannabis reform, but for now, the issue remains sidelined. Until then the industry struggles and waits.